Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis

JAMA

Volumn 292, Issue 13, 2004, Pages 1581-1587

  Smith, Nicholas L ^a,b   Heckbert, Susan R ^a,c   Lemaitre, Rozenn N ^b   Reiner, Alex P ^a   Lumley, Thomas ^a   Weiss, Noel S ^a   Larson, Eric B ^c   Rosendaal, Frits R ^d   Psaty, Bruce M ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CLIMACTERIUM; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; FEMALE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HYPERTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; VEIN THROMBOSIS; ESTROGEN THERAPY; MIDDLE AGED; RISK; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CLIMACTERIC; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); ESTROGENS, ESTERIFIED (USP); FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; RISK; VENOUS THROMBOSIS;

EID: 4644268401     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.13.1581     Document Type: Article

References (32)

1. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132:689-696.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
3. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
4. Ansbacher R. The pharmacokinetits and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol. 2001;184:255-263.
5. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol. 1995;35(9 suppl):18S-24S.
6. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA. 2004;291:1610-1620.
7. Good WR, John VA, Ramirez M, Higgins JE. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms: Alora Study Group. Climacteric. 1999;2:29-36.
8. von Holst T, Lang E, Winkler U, Keil D. Bleeding patterns in peri- and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. Maturitas. 2002;43:265-275.
9. Kaplan RC, Psaty BM, Kriesel D, et al. Replacing short-acting nifedipine with alternative medications at a large health maintenance organization. Am J Hypertens. 1998;11:471-477.
10. Andrade SE, Gurwitz JH, Cernieux J, Fish LS. Evaluation of a formulary switch from conjugated to esterified estrogens in a managed care setting. Med Care. 2000;38:970-975.
11. Gardner J, Scholes D, Baluch W, Krauss R. Acceptability of a substitution of estrogen replacement therapy to women enrolled in a health maintenance organization. J Womens Health. 1998;7:1027-1031.
12. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 1994;154:1333-1339.
13. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
14. Heckbert SR, Weiss NS, Koepsell TD, et al. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med. 1997;157:1330-1336.
15. Lobo RA. Clinical review 27: effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991;73:925-930.
16. Raghunathan TE, Solenberger PW, van Hoewyk J. IVEware: Imputation and Variance Estimation Software. Ann Arbor: Institute for Social Research, University of Michigan; 1998.
17. Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med. 1998;217:6-16.
18. Jurgens RW Jr, Downey LJ, Abernethy WD, et al. A comparison of circulating hormone levels in postmenopausal women receiving hormone replacement therapy. Am J Obstet Gynecol. 1992;167:459-460.
19. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95:2855-2859.
20. Meijers JC, Middeldorp S, Tekelenburg W, et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis. Thromb Haemost. 2000;84:9-14.
21. Cushman M, Psaty BM, Meilahn EN, Dobs AS, Kuller LH. Post-menopausal hormone therapy and concentrations of protein C and antithrombin in elderly women. Br J Haematol. 2001;114:162-168.
22. Di Bitondo R, Hall AJ, Peake IR, Iacoviello L, Winship PR. Oestrogenic repression of human coagulation factor VII expression mediated through an oestrogen response element sequence motif in the promoter region. Hum Mol Genet. 2002;11:723-731.
23. Nozaki M, Ogata R, Koera K, et al. Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy. Climacteric. 1999;2:124-130.
24. Lowe CD, Upton MN, Rumley A, et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein: a cross-sectional population survey. Thromb Haemost. 2001;86:550-556.
25. Middeldorp S, Meijers JC, van den Ende AE, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost. 2000;84:4-8.
26. Teede HJ, McGrath BP, Smolich JJ, et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol. 2000;20:1404-1409.
27. Koh KK, Horne MK III, Cannon RO III. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women. Thromb Haemost. 1999;82:626-633.
28. Gottsater A, Rendell M, Hulthen UL, Berntorp E, Mattiasson I. Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med. 2001;249:237-246.
29. Van Baal WM, Emeis JJ, Kenemans P, et al. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest. 1999;29:913-921.
30. Meyer WR, Costello N, Straneva P, et al. Effect of low-dose estrogen on hemodynamic response to stress. Fertil Steril. 2001;75:394-399.
31. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Arch Intern Med. 1997;157:2609-2615.
32. Friebely JS, Shifren JL, Schiff I, Regestein QR. Preliminary observations on differing psychological effects of conjugated and esterified estrogen treatments. J Womens Health Gend Based Med. 2001;10:181-187.